In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017-Reference-Cited by-同舟云学术

In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017

Published:2019-08 Issue:8 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Pfaller M. A.¹²,Huband M. D.¹,Flamm R. K.¹,Bien P. A.³,Castanheira M.¹

Affiliation:

1. JMI Laboratories, North Liberty, Iowa, USA

2. University of Iowa, Iowa City, Iowa, USA

3. Amplyx Pharmaceuticals, San Diego, California, USA

Abstract

Current antifungal agents cover a majority of opportunistic fungal pathogens; however, breakthrough invasive fungal infections continue to occur and increasingly involve relatively uncommon yeasts and molds, which often exhibit decreased susceptibility. APX001A (manogepix) is a first-in-class small-molecule inhibitor of the conserved fungal Gwt1 protein. This enzyme is required for acylation of inositol during glycosylphosphatidylinositol anchor biosynthesis.

Funder

Amplyx Pharmaceuticals

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00840-19

Reference45 articles.

1. In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories

2. New Horizons in Antifungal Therapy

3. Newer antifungal agents